FLS – Fast Lean Smart UK Welcomes German Ambassador

 FLS – Fast Lean Smart UK welcomed The German Ambassador, Miguel Berger for a visit to its Northern Office at Sci-Tech Daresbury. The visit included a tour of the National Science and Innovation Campus, a specialist development for the ‘open innovation’ model of work across the commercial STEM (Science, Technology, Engineering, Maths) sector.

FLS was introduced as a leading developer of AI and Machine Learning technology and FLS UK’s Senior Leadership Team discussed their progress since bringing the unique PowerOpt algorithm to the UK market in 2012.

“This was of particular interest to His Excellency,” said Jeremy Squire, Managing Director of FLS – FAST LEAN SMART UK. “PowerOpt began life in Cologne, Germany and continues as the bedrock of Europe’s leading field service scheduling and route planning software, FLS VISITOUR.

“FLS continues to grow and international collaboration maximises our ability to produce next generation, real-time solutions for the world stage. It was an honour to present our success with ‘open innovation’ and particularly fitting as we celebrate FLS’ 30th anniversary this year.”

His Excellency Miguel Berger commented, “An impressive visit to Sci-Tech Daresbury. Great to see how companies receive technological support by SCFT in order to further develop their products.”

FLS VISITOUR recently gained a listing on the UK Government’s G-Cloud framework and continues to win awards for innovation and supporting the transformation of its customers’ field operations, including Technology Innovation of the Year at the 2022 European Field Service Awards.

About FAST LEAN SMART

FAST LEAN SMART provides world-leading AI-powered technology across many sectors including housing, engineering, and manufacturing. Deploying its software FLS VISITOUR enables the intelligent optimisation of schedules and resources in real time, delivering more flexibility, route planning ability, and enormous cost savings.

FLS continues to grow throughout the UK, working with Amey Secure Infrastructure, Your Housing Group, Axis Europe PLC, T Brown Group, JLA Group and HomeServe, providing best-of-breed scheduling solutions.

A recent customer satisfaction survey ranked FLS among the highest rated field force scheduling on the market with a 9.6 out of 10 rating.

For more about FLS, visit: www.fastleansmart.com/en/.

FLS – FAST LEAN SMART

James Alex Waldron

+44 1183 800189

https://www.fastleansmart.com/en/

ContactContact

Categories

  • Software

Fusion CPA Impacts Charities Across the World

 Tax and accounting specialists at Fusion CPA set themselves a goal: not only to drive revenue and positively influence the finances of their clients, but also to make a difference where it is needed most. Through the company’s Fusion Day of Giving, staffers were challenged to roll up their sleeves and get to work by making a difference to a range of charitable causes.

Because of the company’s remote work model, which enables them to employ staff from various regions across the world, the charity drive reached organizations across the globe.

From spending time at an array of organizations, to donating in monetary form, the Fusion Day of Giving made a difference to the following charitable causes:

– Community outreach reading programmes

– Educational support for low income families

– Sports mentoring

– Hurricane support and relief

– Endangered species conservation

– Animal rehabilitation

– Care for orphans

Fusion CPA Founder and CEO Trevor McCandles has always been very involved in the community around him and has a heart for those with challenging circumstances. Trevor established the Fusion Day of Giving to allow each member of his team the opportunity to make a direct impact to the cause that they are passionate about.

“It is easy to become consumed with the responsibilities tied to your own work and life, but when you take a second to step away from that, and be deliberate about doing good, it not only aids people who need it most, but also grants you the opportunity to realign with that which matters most,” says Trevor.

Having a remote workforce means that as a business we were able to empower staff to help the many communities around them, allowing us as a business to make a difference in the United States right through to Africa, Puerto Rico and beyond.

Just as McCandless planned, his team not only made a difference, but felt a difference too.

“Visiting the Educentre and Babies Homes to lend a pair of hands was not only an extremely humbling and a beautiful experience, it also opened my eyes to the fact that something as simple as showing care, makes a massive difference in the lives of vulnerable people,” said Roneque Janse Van Rensburg, a member of Fusion CPA’s marketing team.

“I enjoyed being able to give my time and resources to support our local library to provide vital resources and programs for those in our community. The experience was amazing all round,” said Cassie Bell, Tax and Accounting Manager at the firm.

Fusion’s Day of Giving supported 11 charitable causes across six different countries across the world. Staff donated a total of 35 hours of their time.

Fusion CPA is a multi-state tax and accounting firm offering outsourced CPA services, accounting software set up and integration, tax preparation and bookkeeping services, and a whole lot more.

Fusion CPA

Sandra Olivier

404-955-7338

www.fusiontaxes.com

ContactContact

Categories

  • Finance

Tianda Pharma Announces 2022/23 Interim Results

Tianda Pharmaceuticals Limited (“Tianda Pharma” or “the Group”; stock code: 0455.HK) today announced its interim results for the six months ended 30 September 2022 (“the Period”). During the Period, the Group adopted proactive marketing strategy and improved its results notably. Its revenue increased by 5.6% to approximately HK$250 million. Gross profit rose by 10.2% to approximately HK$120 million and profit before taxation, depreciation and amortization turned around from loss of HK$6.9 million in the same period last year to profit of HK$2.3 million for the period.

Recorded strong sales of core products and continued to optimize Chinese medicine business layout

The Group has worked hard cultivating the cardiovascular, cerebrovascular and pediatric disease realms and owns unique generic product pipelines. Boasting notable efficacy and competitive price, Tuoping Valsartan capsules, the Group’s core product for treating cardio-cerebrovascular disease, has been ranked the No. 1 best-selling product in its category in Mainland China since the success in securing first place in the nation’s Centralized Drug Procurement. During the Period, sales of the product reached HK$92.3 million, representing a year-on-year growth of approximately 21%. Tuoen Ibuprofen oral suspension, a pediatric drug, was among the top three in terms of market share in the country due to effective marketing, achieving strong sales of HK$64.0 million for the Period, up approximately 70% year-on-year.

The Group has basically built for itself a complete traditional Chinese medicine (“TCM”) industrial chain, from trading of Chinese medicinal materials, TCM decoction pieces and formula granules to innovative Chinese medicine R&D and international trade. During the Period, it continued to increase operating product varieties, expand sales channels and strengthen procurement sources, including exporting TCM decoction pieces to Australia and planning for importing to China special variety of Chinese medicinal materials from overseas. Insisted on the inheritance and innovation of TCM, it brought in innovative Chinese medicine transformation projects and embarked on cooperation in developing innovative Chinese medicines.

During the Period, overall revenue of TDMalls increased by 81%. The first clinic to adopt the equity investment cooperation model, TDMall (Tsim Sha Tsui) has famous medical experts as shareholders who also participate in the management. Starting to make profit eight months after opening, TDMall (Tsim Sha Tsui) provides valuable experience and serving as a model for expanding the business across the nation and worldwide. The Group is pushing forward with opening a TDMall in Shenzhen, another important step in expanding its presence in the Guangdong-Hong Kong-Macao Bay Area. The Group also continued to invest in “intelligent” development of Chinese medicines. The Chinese medicine cloud technology-based platform “TDMall on Cloud” of the Group played an important role in the Group’s “Free Consultation and Medicine” charity campaign during the fifth wave of COVID-19 outbreaks in Hong Kong, offering comprehensive remote Chinese medicine services to the public.

Strengthened R&D across the board and capability to bring in business, actively expanded revenue sources

The Group has insisted on combining generic drug endeavors with innovation and, via its own R&D efforts and cooperation with external R&D institutions, continued to enrich its product pipelines. During the Period, the Group increased R&D investment, spending HK$12.0 million, up 260% year-on-year, set to allow it to come up with more new products that can become new and strong growth drivers for its medium and long-term development. The Group is currently pursuing 22 R&D projects, including class I innovative Chinese medicines, class III new Chinese medicines, class III chemical drug plus APIs, class IV chemical drugs and healthcare product series. During the Period, the Group actively introduced innovative Chinese medicine transformation projects in which the industry, academia, research and medical sectors come together to develop innovative Chinese medicines for treating chronic heart failure. Such initiatives have given the Group a rich and diversified product development portfolio that covers high-end generic drugs, classic Chinese medicines, modern Chinese medicines and healthcare products. The Group also actively introduced approved proprietary Chinese medicine products. Following the acquisition of the proprietary Chinese medicine product Xiaoer Qingre Zhike Granule last year, it acquired Jianerle Granule, a proprietary Chinese medicine for children during the Period, continuing to expand its pediatric product categories.

In addition, the Group launched contract development and manufacturing organization (“CDMO”) and contract manufacturing organization (“CMO”) businesses to expand its revenue sources and promote business development. As at the end of September 2022, it had seven contracts signed for R&D technology service mainly for liquid pharmaceutical preparations and completed production for two projects during the Period. The two business modes are expected to become growth drivers that can continuously generate revenue for the Group.

Stepped up efforts in three business segments, consolidated business foundation and achieved leapfrog development

To seize the opportunities in the continuously expanding pharmaceutical and healthcare market, the Group will keep growing its three business segments, namely Chinese medicines, medical and healthcare services and pharmaceuticals and medical technologies, in the future. It will also speed up bringing in products and product R&D, strengthen business expansion efforts, and investment and M&As, so as to achieve leapfrog development. For the Chinese medicine business, leveraging the country’s policies to vigorously help the Chinese medicine industry develop, the Group will grasp the policy dividend of TCM and continue to develop the whole industry chain, increasing the trading of Chinese medicinal materials focusing on varieties, while accelerating the development of TCM decoction pieces and formula granules, which have huge market potential. It will also actively invest in the R&D and introduction of innovative Chinese medicines, classic ancient prescriptions of Chinese medicines, finished dosages and proprietary Chinese medicines. For its medical and healthcare services business, the Group will strengthen operation of the TDMalls and speeding up expansion via building its own clinics, franchising and mergers and acquisitions, and as well using different equity investment and cooperation modes. While prioritizing the development in the Guangdong-Hong Kong-Macao Bay Area, the Group will push for nationwide and global reach. At the same time, the Group will continue to improve and perfect its “TDMall on Cloud” app to “enhance user experience”, for better online and offline integration, providing patients with convenient and intelligent high-quality Chinese medicine services. On the pharmaceuticals and medical technologies business front, the Group will strive to build up its core product brands such as Tuoping and Tuoen, focusing on developing cardio-cerebrovascular and pediatric products and consolidating relevant advantages. It will also expand its sales network to cover lower-tier markets so as to booster market share and actively expand CDMO and CMO business to boost revenue. In the future, it will apply 3D tactics (BD – business development, ID – investment and development, and R&D – research and development) in developing products with market potential, especially major product types, to provide impetus for long-term sustainable development.

About Tianda Pharmaceuticals Limited

Tianda Pharmaceuticals Limited (“Tianda Pharmaceuticals”, listed on the Hong Kong Stock Exchange, stock code: 0455.HK) implements the following development strategies: development of Traditional Chinese medicine (“TCM”) as its foundation, development of innovative drugs and medical technologies, as well as development of high-quality medical and healthcare services, striving to become a leading pharmaceutical enterprise that sets its footholds in China while seeking to expand its presence worldwide.






Topic: Press release summary



JBM Healthcare Announces FY2023 Interim Results

JBM (Healthcare) Limited (“JBM Healthcare” or the “Group”; Stock Code: 2161), a leading branded healthcare products marketer and distributor in Hong Kong, has announced today the interim results of the Group for the six months ended 30 September 2022 (the “Reporting Period”).

KEY HIGHLIGHTS

— Period-on-period revenue up by 25%, totaled HK$236.8 million

— Profit attributable to equity shareholders increased by 116%, amounting to HK$21.6 million

— The Board declares an interim dividend of HK0.5 cent per share

— Proprietary Chinese medicines business witnessed robust growth of 53.1%

— Cross-border e-commerce business gained traction alongside expanded product offerings and growing customer traffic

— Foreseeable growth of traditional Chinese medicine (TCM) business bolstered by favourable policies for gaining access to Greater Bay Area markets.

Despite the lingering effects of the COVID-19 pandemic and the volatile economic sentiment in Hong Kong, the Group continued to perform in a resilient manner posting total revenue of HK$236.8 million in the Reporting Period, delivering a notable increase of 25% period-on-period. Profit attributable to equity shareholders also increased by 116% period-on-period to HK$21.6 million. Such growth was primarily due to the easing of local social distancing policies, which buttressed retail spending sentiment and led to a gradual recovery of the Group’s overall sales, alongside a financial subsidy from the HKSAR Government through the Employment Support Scheme.

The Board declares the payment of an interim dividend for the six months ended 30 September 2022 of HK0.5 cent per share.

Resilient Performance Sustained by Robust Branded Portfolio

During the Reporting Period, the Group has made sound progress in developing its cross-border e-commerce platform, expanding the access of its products to a growing consumer base in Mainland China. Furthermore, the Group continued to implement its growth strategies to keep pace with consumer demand and market opportunities, further leveraging its unique strength to reinforce the Group’s competitive position as a farsighted branded healthcare player in Asia. The promising performance was underpinned by the Group’s brand management and strong commercial execution capabilities, as well as established sales network.

For the branded medicines business, sales revenue saw a decline of 10.3% period-on-period to HK$56.9 million, mainly due to the adverse impact of the pandemic on retail consumption in Hong Kong and Macau Nonetheless, the category-leading AIM Atropine Eye Drops brand continued to achieve promising growth realising 11.3% sales growth.

Regarding the proprietary Chinese medicines business, sales revenue delivered robust growth of 53.1%, amounting to HK$163 million, which was driven by strong momentum from its Concentrated Chinese Medicine Granules (“CCMG”) business as a result of rising recognition and acceptance towards the adjunct therapeutic benefits of Chinese medicine amongst the general public. Our category leading brand, Po Chai Pills, also posted a remarkable growth of over 60% during the Reporting Period.

As for health and wellness products, sales revenue registered a decline of 13.3% to HK$16.9 million during the Reporting Period, which was mainly due to lower sales of certain products in the Hong Kong retail sector, though offset by growth from Oncotype DX and the Pantogar shampoo and tonic series. Oncotype DX posted a robust growth of 19.7% with a sustained momentum during the Reporting Period. With respect to Pantogar, an effective treatment for hair loss as substantiated by clinical studies, it also gained notable success via e-commerce platforms and professional hair salon channels. Pantogar sales was boosted by the launch of a new shampoo and tonic series that feature specialised formulations for women and men.

Accelerating E-commerce Development

The development of the Group’s PRC cross-border e-commerce business continued to gather momentum as a result of its sustained efforts to drive expansion across product offerings, platform footholds, and customer traffic.

The two self-operated flagship stores on Tmall Global Marketplace and JD Worldwide achieved significant progress in expanding market share and customer base during the Reporting Period, bolstered by the effective operation and customer service support of its dedicated cross-border e-commerce team. The Group’s flagship store has earned a top 8 ranking at Tmall, while Ho Chai Kung Tji Thung San has claimed a top 5 ranking in the pain-killer category of the platform during the Reporting Period.

The Group has continued to strengthen its partnership and operation with major PRC cross-border e-commerce platform customers, which witnessed a notable increase of pre-event purchase orders from B2B partners for the “6.18” and “Double 11” promotions during the Reporting Period. Apart from OTC products, the Group has been also actively enhancing its portfolio with products for tapping new potential categories to target a wider range of consumer groups. The Group’s skincare and beauty products are currently sold through VIP Shop, a popular cross-border e-commerce platform for branded lifestyle products, and will be available via a growing array of cross-border e-commerce platforms.

Capturing Growth Potential of Chinese Medicines

The Group’s proprietary Chinese medicine business also benefits from the government bureaus’ collaborative support in facilitating the entry of Hong Kong’s traditional proprietary Chinese medicines into the Greater Bay Area. Leveraging the streamlined measures for the Group’s proprietary Chinese medicines portfolio to register with the Guangdong Provincial Medical Products Administration, it has successfully secured approval for registering its medicated oil brands Shiling Oil and Konsodona Medicated Oil in the Greater Bay Area.

Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, said, “In the wake of adverse market sentiments, pragmatism and persistence have never been more important as we navigate through the challenges that the pandemic has introduced to the business landscape. The pandemic has heightened health awareness and accelerated consumers’ shift towards a more proactive approach in managing their health and wellness, which will further shore up self-care demand. The Group, as a key proprietary Chinese medicine and CCMG market player in Hong Kong, is also well poised to tap the burgeoning market in the Greater Bay Area, supported in part by favorable policies that encourage the development of TCM in the region and which will create more prospective business opportunities.

Looking ahead, we remain optimistic about the outlook for the healthcare industry. Adhering to our mission of enabling better health through self-care, we will continue to focus on developing our growth strategies based on the objectives of greater resilience and operational efficiency, and capitalise on market opportunities by helping consumers better manage their health through quality and well-trusted branded healthcare products.”

About JBM (Healthcare) Limited (Stock Code: 2161)

JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia and certain other countries. The Group is a unique field player with marketing expertise and a drug heritage that prioritises product efficacy and quality to meet consumers’ healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex, BITE-X, Mederma Kids, Tong Tai Chung Woodlok Oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021.

For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk.






Topic: Press release summary



PASSING OUT PARADE – AUTUMN TERM 2022


In a spectacular Passing out Parade (POP) held at Indian Naval Academy, Ezhimala, on Saturday, 26 Nov 22, 252 trainees comprising Midshipmen of 103 Indian Naval Academy Course, cadets of 36 Naval Orientation Course (Regular), 36 Naval Orientation Course (Coast Guard), 36 Naval Orientation Course (Foreign), 32, 33 & 34 Naval Orientation Course (Extended) passed out with flying colours, marking the culmination of their ab-initio training. The passing out trainees comprises of 16 foreign cadets from 07 countries and 35 women trainees.


        The Parade was reviewed by Air Marshal Balabhadra Radha Krishna, Chief of Integrated Defence Staff to the Chairman of the Chiefs of Staff Committee (CISC) who awarded medals to meritorious Midshipmen and Cadets on completion of the Ceremonial Review. Vice Admiral Puneet K Bahl, Commandant, Indian Naval Academy was the Conducting Officer.


        The ‘President’s Gold Medal’ for the Indian Naval Academy BTech Course was awarded to Midshipman Anivesh Singh Parihar. The other medal winners were as follows:


        (a)        CNS Silver medal for INAC B. Tech Course –        Midshipman Manoj Kumar


 (b)        FOC-in-C South Bronze Medal for INAC B. Tech Course- Midshipman Vishwajeet Vijay Patil


        (c)        CNS Gold Medal for NOC (33 Ext) – Cadet Gaurav Rao


        (d)        FOC-in-C South Silver Medal for NOC (33Ext) – Cadet Raghav Sareen


        (e)        Commandant, INA Bronze Medal for NOC (33 Ext) – Cadet Aaron Ajith John


        (f)         CNS Gold Medal for NOC (Regular) – Cadet P Yasmitha N


        (g)        Commandant, INA Silver Medal for NOC (Regular)- Cadet KR Padmavathi


        (h)        Zamorin Trophy for Best All round women cadet – Cadet Yasmitha N


        (j)         CNS Gold Medal for NOC (34 Ext)- Cadet Harsh Ashok Sharma


 (k)        Commandant, INA Silver Medal for NOC (34 Ext)- Cadet Pavan Kumar Gandi


(l)         Commandant, INA Bronze Medal for NOC (34 Ext) – Cadet Tejas Anup Srivastava


        The successful trainees marched with their gleaming swords and rifles held in salute, past the Academy’s Quarterdeck, in Slow March, to the traditional notes of ‘Auld Lang Syne’ – the poignant farewell tune played by armed forces around the world when bidding adieu to colleagues and comrades, for their ‘Antim Pag’ or final step at the Indian Naval Academy.


        Air Marshal Balabhadra Radha Krishna congratulated the trainees on parade for their impeccable turnout, smart drill and movements on parade. The Reviewing Officer emphasised on the core values of duty, honour and courage. The Reviewing Officer and other dignitaries shipped the stripes of passing out trainees and congratulated them for their successful completion of the rigorous training. These officers will proceed to various Naval ships and establishments to further consolidate their training in specialised fields.



 


­_________________________________________________________________


VMJSN                                                                                        150/22




(Release ID: 1879138)
Visitor Counter : 323